Marcella SW et al. – Statin use was associated with substantial protection against prostate cancer death, adding to the epidemiologic evidence for an inhibitory effect on prostate cancer.
This was a matched case-control study.
Cases were residents of New Jersey ages 55 to 79years who died from prostate cancer between 1997 and 2000.
The cases were matched individually to population-based controls by 5-year age group and race.
Medication data were obtained identically for cases and controls from blinded medical chart review.
Conditional logistic regression was used to adjust for confounders.
In total, 718 cases were identified, and cooperation was obtained from 77% of their spouses (N=553).
After a review of medical records, 387 men were eligible, and 380 were matched to a control.
The unadjusted odds ratio was 0.49 (95% confidence interval, 0.34-0.70) and decreased to 0.37 (P<.0001) after adjusting for education, waist size, body mass index, comorbidities, and antihypertensive medication.
There was little difference between lipophilic and hydrophilic statins, but more risk reduction was noted for high-potency statins (73%; P<.0001) compared with low-potency statins (31%; P=.32).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.